Skip to main content

Table 2 Multivariate analyses of prognostic factors for patients with early-stage and locoregionally advanced NPC

From: Pretreatment platelet count improves the prognostic performance of the TNM staging system and aids in planning therapeutic regimens for nasopharyngeal carcinoma: a single-institutional study of 2,626 patients

Endpoint Variable a HR 95% CI P value
Early-stage NPC ( n = 1,057)     
Overall survival Age (>45 vs. ≤45 years) 1.586 1.213–2.075 0.001
  Sex (female vs. male) 1.409 1.019–1.949 0.038
  T category (T2 vs. T1) 1.352 1.014–1.803 0.040
  N category (N1 vs. N0) 2.326 1.732–3.124 <0.001
  PLT count (>300 × 109/L vs. ≤300 × 109/L) 2.057 1.510–2.804 <0.001
Locoregional recurrence–free survival N category (N1 vs. N0) 1.566 1.053–2.328 0.027
Distant metastasis–free survival Age (>45 vs. ≤45 years) 1.387 0.970–1.984 0.073
  T category (T2 vs. T1) 1.899 1.249–2.888 0.003
  N category (N1–3 vs. N0) 2.532 1.677–3.824 <0.001
  PLT count (>300 × 109/L vs. ≤300 × 109/L) 1.788 1.167–2.739 0.008
Locoregionally advanced NPC ( n = 1,569)
Overall survival Age (>45 vs. ≤45 years) 1.657 1.397–1.966 <0.001
  Gender (female vs. male) 1.452 1.163–1.813 0.001
  PLT count (>300 × 109/L vs. ≤300 × 109/L) 1.716 1.407–2.093 <0.001
Locoregional recurrence–free survival Age (>45 vs. ≤45 years) 1.541 1.238–2.037 <0.001
Gender (female vs. male) 1.561 1.259–1.888 0.001
Distant metastasis–free survival N category (N1–3 vs. N0) 2.014 1.331–3.047 0.001
PLT count (>300 × 109/L vs. ≤300 × 109/L) 1.859 1.393–2.481 <0.001
  1. aThe parameters listed in this column were included in the multivariate analysis using Cox proportional hazards model by backward elimination. PLT, platelet; CRT, chemoradiotherapy; RT, radiotherapy; HR, hazard ratio; CI, confidence interval.